Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Advanced Chart

Key Stats

Today's Range
$13.26
$15.35
50-Day Range
$13.60
$17.07
52-Week Range
$12.63
$18.68
Volume
51,728 shs
Average Volume
90,136 shs
Market Capitalization
$17.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

Pieris Pharmaceuticals Inc
Palvella Therapeutics Inc (PVLA)
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
One new option listing and one option delisting on December 16th
See More Headlines

PIRS Stock Analysis - Frequently Asked Questions

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting analysts' consensus estimates of ($19.20). The biotechnology company had revenue of $4.06 million for the quarter, compared to the consensus estimate of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 80.93% and a negative net margin of 39.71%.

Shares of Pieris Pharmaceuticals reverse split before market open on Tuesday, April 23rd 2024.The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), GE Aerospace (GE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/02/2021
Today
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PIRS
CIK
1583648
Employees
140
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($12.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.54 million
Net Margins
-39.71%
Pretax Margin
-1,179.96%
Return on Equity
-80.93%
Return on Assets
-59.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.82
Quick Ratio
4.82

Sales & Book Value

Annual Sales
$42.81 million
Price / Sales
0.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$21.66 per share
Price / Book
0.63

Miscellaneous

Outstanding Shares
1,320,000
Free Float
1,236,000
Market Cap
$17.95 million
Optionable
Optionable
Beta
0.61

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PIRS) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners